PE20130496A1 - Tratamiento de artritis por lupus usando laquinimod - Google Patents

Tratamiento de artritis por lupus usando laquinimod

Info

Publication number
PE20130496A1
PE20130496A1 PE2012001382A PE2012001382A PE20130496A1 PE 20130496 A1 PE20130496 A1 PE 20130496A1 PE 2012001382 A PE2012001382 A PE 2012001382A PE 2012001382 A PE2012001382 A PE 2012001382A PE 20130496 A1 PE20130496 A1 PE 20130496A1
Authority
PE
Peru
Prior art keywords
laquinimod
lupus arthritis
arthritis treatment
treatment
active lupus
Prior art date
Application number
PE2012001382A
Other languages
English (en)
Inventor
Asi Haviv
Nora Tarcic
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PE20130496A1 publication Critical patent/PE20130496A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UN METODO DE TRATAMIENTO DE ARTRITIS POR LUPUS ACTIVO CON LAQUINIMOD QUE CONSISTE EN ADMINISTRAR PERIODICAMENTE POR AL MENOS 12 SEMANAS UNA CANTIDAD DE 0.5-1.0 mg/dia DE LAQUINIMOD SODICO EN FORMA ORAL, CONJUNTAMENTE CON CORTICOIDES, INMUNOSUPRESORES, FARMACOS ANTIPALUDICOS, ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO METODO REDUCE LOS SINTOMAS DE ARTRITIS POR LUPUS ACTIVO COMO HINCHAZON DE ARTICULACIONES.
PE2012001382A 2010-03-03 2011-03-02 Tratamiento de artritis por lupus usando laquinimod PE20130496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33935510P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
PE20130496A1 true PE20130496A1 (es) 2013-05-08

Family

ID=44531530

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001382A PE20130496A1 (es) 2010-03-03 2011-03-02 Tratamiento de artritis por lupus usando laquinimod

Country Status (21)

Country Link
US (4) US20110217295A1 (es)
EP (1) EP2542080B1 (es)
JP (2) JP2013521305A (es)
KR (1) KR20130036217A (es)
CN (1) CN102781239B (es)
AU (1) AU2011223702B2 (es)
BR (1) BR112012022064A2 (es)
CA (1) CA2791711A1 (es)
CL (1) CL2012002422A1 (es)
CO (1) CO6630086A2 (es)
EA (1) EA201290859A1 (es)
ES (1) ES2601819T3 (es)
HK (1) HK1177876A1 (es)
MX (1) MX342001B (es)
NZ (1) NZ602512A (es)
PE (1) PE20130496A1 (es)
PL (1) PL2542080T3 (es)
PT (1) PT2542080T (es)
SG (2) SG10201501539SA (es)
WO (1) WO2011109536A1 (es)
ZA (1) ZA201207125B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5832716B2 (ja) * 2005-10-19 2015-12-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶，及びその製造方法
KR20160013273A (ko) 2006-06-12 2016-02-03 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
PT2682120T (pt) 2007-12-20 2016-11-07 Teva Pharma Preparações de laquinimod estáveis
KR20110048571A (ko) * 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
EP3028572A1 (en) * 2009-06-19 2016-06-08 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
EA025468B1 (ru) * 2009-07-30 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение болезни крона с применением лаквинимода
PL3064206T3 (pl) 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
CA2791709A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
CA2791691A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
JP2013521305A (ja) * 2010-03-03 2013-06-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いるループス関節炎の治療
SG186948A1 (en) 2010-07-09 2013-02-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2013055907A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
WO2013123419A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
AU2013341506A1 (en) 2012-11-07 2015-06-04 Teva Pharmaceutical Industries Ltd. Amine salts of Laquinimod
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
JP2016513665A (ja) 2013-03-14 2016-05-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドの経皮製剤
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
US6852323B2 (en) * 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
AU2004251750A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
AU2005231467A1 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
CA2579038A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
JP5905184B2 (ja) * 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
JP5832716B2 (ja) * 2005-10-19 2015-12-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶，及びその製造方法
ZA200803327B (en) * 2005-10-26 2009-09-30 Serono Lab Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
PL2676967T3 (pl) * 2006-02-28 2019-12-31 Biogen Ma Inc. Metody leczenia chorób zapalnych i autoimmunologicznych za pomocą natalizumabu
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
KR20080104343A (ko) * 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2007139887A2 (en) * 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
KR20160013273A (ko) * 2006-06-12 2016-02-03 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
US20080090897A1 (en) * 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
WO2009009529A1 (en) * 2007-07-11 2009-01-15 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
PT2682120T (pt) * 2007-12-20 2016-11-07 Teva Pharma Preparações de laquinimod estáveis
KR20110048571A (ko) * 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
EP3028572A1 (en) * 2009-06-19 2016-06-08 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
EA025468B1 (ru) * 2009-07-30 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение болезни крона с применением лаквинимода
PL3064206T3 (pl) * 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
JP2013521305A (ja) * 2010-03-03 2013-06-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いるループス関節炎の治療
SG186948A1 (en) * 2010-07-09 2013-02-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CA2901849A1 (en) * 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof

Also Published As

Publication number Publication date
SG10201501539SA (en) 2015-04-29
MX2012010071A (es) 2012-10-03
WO2011109536A1 (en) 2011-09-09
US20110217295A1 (en) 2011-09-08
US20160213663A1 (en) 2016-07-28
ZA201207125B (en) 2014-06-25
MX342001B (es) 2016-09-09
CN102781239A (zh) 2012-11-14
SG183515A1 (en) 2012-10-30
PT2542080T (pt) 2016-11-16
EP2542080A4 (en) 2013-07-17
JP2016196473A (ja) 2016-11-24
JP2013521305A (ja) 2013-06-10
ES2601819T3 (es) 2017-02-16
CL2012002422A1 (es) 2012-12-21
AU2011223702A1 (en) 2012-10-25
US20150086549A1 (en) 2015-03-26
CO6630086A2 (es) 2013-03-01
US20130184310A1 (en) 2013-07-18
CN102781239B (zh) 2015-01-21
BR112012022064A2 (pt) 2015-09-08
KR20130036217A (ko) 2013-04-11
EP2542080A1 (en) 2013-01-09
HK1177876A1 (zh) 2013-08-30
NZ602512A (en) 2014-07-25
CA2791711A1 (en) 2011-09-09
AU2011223702B2 (en) 2016-07-14
PL2542080T3 (pl) 2017-02-28
EP2542080B1 (en) 2016-08-31
EA201290859A1 (ru) 2013-04-30

Similar Documents

Publication Publication Date Title
PE20130496A1 (es) Tratamiento de artritis por lupus usando laquinimod
PE20130690A1 (es) Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
TN2015000135A1 (en) Modified release formulations for oprozomib
CY1121973T1 (el) Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
EA201591150A1 (ru) Твердая единая форма с высоким содержанием фексофенадина и способ ее получения
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
IN2014MN01806A (es)
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.

Legal Events

Date Code Title Description
FC Refusal